Integer Holdings (NYSE: ITGR) has spent the past year on the wrong side of the tape, sliding nearly 38% even as the broader market kept climbing. Then came a move that instantly put the name back on investor radar: Newtyn Management disclosed a new position worth roughly $43.14 million, a size that signals more than casual interest in a bruised chart.
For a company that rarely grabs headlines, the trade reads like a statement. Integer is not a meme stock. It’s a medical-device outsource manufacturer that lives inside the supply chains of major OEMs, where switching costs are high, qualification cycles are long, and reliability matters. A large new stake in a down-and-out operator often suggests a specific view: the fundamentals may be steadier than the share price implies, and the pathway back can be built through execution rather than hype.
The $43 million entry that changed the conversation
In a filing dated February 17, Newtyn Management reported a new stake in Integer Holdings (NYSE: ITGR) totaling 550,000 shares, valued at about $43.14 million. The position represented roughly 4.53% of the firm’s 13F-reportable assets under management as of December 31, 2025, making it one of the fund’s more meaningful allocations right out of the gate.
If you want the cleanest way to verify the position sizing and reporting details, the numbers are available directly in the SEC filing.
At the February 17 close, Integer shares were around $87.66. The stock’s one-year decline left it materially behind the S&P 500, and the underperformance has been sharp enough that even long-term holders have been forced to re-underwrite the story.
Integer’s business is built for durability, not drama
Integer Holdings (NYSE: ITGR) operates in a corner of healthcare that tends to be stable, cash-focused, and operationally intense. The company designs, develops, and manufactures a broad portfolio of medical-device components and finished devices, spanning cardiac rhythm management systems, neuromodulation products, vascular and orthopedic instruments, and customized battery solutions.
As an outsourced manufacturer, Integer’s value is tied to process quality, regulatory discipline, and deep integration with customer programs. These relationships can become “sticky” over time, because qualification and validation work is not easily replicated overnight. In that sense, the model resembles industrial manufacturing with healthcare-grade standards and long product lifecycles.
That backdrop is exactly why a large new institutional position can matter. This is not a narrative that changes overnight, but one that can shift quickly when large investors believe the gap between share price and operating reality has widened too far.
The numbers investors are watching in 2026
The recent operating picture has been more resilient than the stock action suggests. Integer reported full-year sales growth of about 8% to roughly $1.85 billion, while adjusted EPS rose about 21% to around $6.40. Adjusted EBITDA reached approximately $402 million, up about 12% year over year, and operating cash flow for 2025 was roughly $196 million.
The balance sheet remains a central part of the investor debate. Net debt sits near $1.19 billion, roughly 3.0x adjusted EBITDA. Management has indicated an expected leverage range of about 2.5x to 3.5x through 2026, and that band will be read as a test of discipline: maintain earnings power, protect margins, and keep deleveraging in motion.
Guidance for 2026 implies GAAP revenue that is flat to slightly lower, with adjusted earnings expected to hold up better than top-line optics might suggest. In a market that’s been punishing anything that looks like deceleration, that mismatch between “flat sales” and “steady earnings” can create volatility — and opportunity — depending on execution.
Newtyn’s portfolio context adds another angle
Newtyn’s filing also shows a portfolio that leans toward distinct, catalyst-friendly names. After the report, the firm’s top holdings included Adient (NYSE: AD), Indivior (NASDAQ: INDV), QuidelOrtho (NASDAQ: QDEL), Enviri (NYSE: NVRI), and Theravance Biopharma (NASDAQ: TBPH).
Against that mix, Integer (NYSE: ITGR) looks like a different tool in the kit: less binary, more operational. The upside case isn’t built on a single clinical readout or one regulatory swing. It’s built on steady organic growth, margin improvement, and balance-sheet progress — the kind of compounding story that can feel invisible until it isn’t.
The setup for investors who like “quiet” turnarounds
The central tension around Integer (NYSE: ITGR) is straightforward. The stock has already priced in a lot of pessimism, reflected in the roughly 38% one-year drop. Meanwhile, the company is still producing real cash flow and posting meaningful profitability metrics for a $3 billion-ish market-cap manufacturer in a regulated sector.
That doesn’t remove risk. Medical-device outsourcing is capital-intensive, and any slip in execution can show up quickly in margins. Customers are demanding, quality standards are unforgiving, and integration work across global operations must stay tight. But the same traits that make the business demanding also reinforce the “embedded supplier” profile that long-term investors often prefer.
For readers tracking this name now, the near-term debate likely won’t be about headlines. It will be about a few repeatable checkpoints: evidence of margin stability, continued cash generation, and a steady glide path on leverage. If those boxes stay checked, the stock’s reset valuation can start to look less like a warning and more like an opening.
You May Also Like
If you want more US market coverage like this on Swikblog, you may also like: Swikblog.
